Clinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.

PureTech Health is a publicly traded biopharmaceutical company that discovers, develops, and commercializes breakthrough medicines by founding and funding a network of subsidiary companies, including Celea Therapeutics.